Momeson Convicap Inhalation Capsule
Mometasone Furoate
220 mcg
Incepta Pharmaceuticals Ltd.
| Pack size | 30's Pack |
|---|---|
| Unite Price | 10.00 BDT |
Indications
Momeson Convicap Inhalation Capsule is used for:
Allergic rhinitis, Nasal polyps, Asthma prophylaxis
Adult Dose
Nasal
Allergic rhinitis
Adult: Nasal Treatment and prophylaxis of allergic rhinitis Adults: 100 mcg (2 sprays) in each nostril once daily, increased to 200 mcg into each nostril once daily if needed. Maintenance: 50 mcg in each nostril daily.
In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with Mometasone Nasal Spray is recommended 2 to 4 weeks prior to the anticipated start of the pollen season.
Nasal polyps:
100 mcg (2 sprays) in each nostril once daily; may increase to bid after 5-6 wk if needed.
Inhalation
Asthma prophylaxis:
Mild to moderate: Initially, 400 mcg once daily in the evening. Maintenance: 200 mcg once to bid.
Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.
Child: Mild to moderate: Initially, 400 mcg once daily. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.
Child Dose
Nasal
Allergic rhinitis
Child: 2-11 yr: 50 mcg (1 spray) in each nostril daily; Child: >12 yr: 100 mcg in each nostril daily.
Inhalation
Asthma prophylaxis:
Child: Mild to moderate: Initially, 400 mcg once daily. Maintenance: 200 mcg once to bid.
Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.
Renal Dose
Administration
Contra Indications
Hypersensitivity, Immunosuppressed patients, Tuberculosis, Status asthmaticus or other acute asthma episode necessitating intensive measures, Known hypersensitivity to milk proteins or any other ingredients
Precautions
Respiratory tract tuberculosis, untreated fungal or bacterial infections, viral or parasitic infections, ocular herpes simplex
Nasal septum perforation, epistaxis, wheezing
Cataracts, glaucoma, increased intraocular pressure
Risk of more serious or fatal course of chickenpox and measles in susceptible individuals; avoid use in unvaccinated or immunologically unexposed children or adults
Deaths from adrenal insufficiency have occurred after abrupt withdrawal of oral steroids; taper withdrawal gradually
May retard growth in children
Immunocompromised patients
Infections of nose and pharynx, including Candida albicans
Excessive use may suppress hypothalamic-pituitary-adrenal function
During periods of stress or severe status asthmaticus, patient may require supplementary systemic corticosteroids immediately; carry warning card to that effect
Long-term administration reduces bone mineral density
Pregnancy-Lactation
Pregnancy
Inhalation
There are no randomized clinical studies in pregnant women
Clinical considerations
In women with poorly or moderately controlled asthma, there is an increased risk of several perinatal adverse outcomes such as preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate
Closely monitor pregnant women with asthma and adjust medication as necessary to maintain optimal asthma control
Lactation
There are no available data on the presence in human milk, the effects on the breastfed child, or the effects on milk production
Other inhaled corticosteroids, similar to mometasone furoate, are present in human milk
Consider developmental and health benefits of breastfeeding along with the mother’s clinical need and any potential adverse effects on the breastfed infant from mometasone inhaled or from the underlying maternal condition
Nasal
Pregnancy category: C
Lactation: Unknown whether distributed in breast milk
Interactions
Increased risk of hypokalaemia with amphotericin B, potassium-wasting diuretics. Decreases hypoglycaemic effects of antidiabetic drugs. Increased serum levels with antifungals (imidazole). Increased risk of tendinopathies with fluoroquinolones.
Side Effects
Side effects of Mometasone Furoate :
>10%
Headache (26%), Viral infection (14%), Pharyngitis (12%), Epistaxis (11%)
1-10%
Cough (7%), Upper respiratory tract infection (6%), Dysmenorrhea (5%)
Frequency Not Defined
Loss of taste, Muscle soreness
Mode of Action
Mometasone depresses the formation, release and activity of endogenous inflammatory chemical mediators (e.g. kinins, histamine, liposomal enzymes and prostaglandin). It inhibits the margination and subsequent cell migration to the injury site, reverses vascular dilatation and permeability, resulting in decreased access of cells to the area of injury.
Note
Momeson Convicap 220 mcg Inhalation Capsule generic name is Mometasone Furoate. Momeson Convicap 220 mcg Inhalation Capsule is manufactured by Incepta Pharmaceuticals Ltd.Momeson Convicap is availble in all over Bangladesh.
Mes BD drug index information on Momeson Convicap Inhalation Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.